Stabilized lipid formulation of apoptosis promoter
US8728516B2 · kind B2 · utility
0Cited by
17References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 29, 2010 |
| Grant date | May 20, 2014 |
| Priority date | — |
| Expiry date | Apr 7, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.